Drug intelligence / Profile preview

Oxacillin

Development stage: Approved
Lead developer: GSK
Modality: Small Molecules
Administration: Intravenous, Intramuscular

Overview

Oxacillin is a penicillinase-resistant beta-lactam antibiotic in the penicillin class, primarily used to treat infections caused by susceptible gram-positive bacteria, especially staphylococci. It works by binding to specific penicillin-binding proteins (PBPs) inside the bacterial cell wall, inhibiting the final stage of bacterial cell wall synthesis and leading to cell lysis. Oxacillin is stable against hydrolysis by many beta-lactamases, including penicillinases and extended-spectrum beta-lactamases. It is administered intravenously or intramuscularly for various staphylococcal infections[1][2][3][4][5].

Brand names: BactocillOxacillin Sodium ADD-Vantage
Other names: oxacillin sodium

Targets

PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on Oxacillin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oxacillin.

Explore the full profile